MoonLake Immunotherapeutics' CFO Sells 39K Shares
Key Points
The executive sold 39,120 shares on June 22.
The sale represented 3.4% of Bodenstedt's direct holdings.
Bodenstedt retains 1,115,435 Class A ordinary shares.
- 10 stocks we like better than MoonLake Immunotherapeutics ›
CFO Sells 39,120 MoonLake Immunotherapeutics Shares Worth ~$862,000
On June 22, Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (NASDAQ:MLTX), sold 39,120 common shares in an open-market transaction valued at approximately $862,000, as disclosed in the SEC Form 4 filing.
Transaction summary
| Metric | Value | Context |
|---|---|---|
| Shares sold (direct) | 39,120 | Open-market shares sold (code 'S') in this filing |
| Transaction value | $862,205 | Based on SEC Form 4 reported price ($22.04) |
| Post-transaction shares (direct) | 1,115,435 | Directly held shares after transaction completion |
| Post-transaction value (direct ownership) | $25.6 million | Based on June 22 market close ($22.16) |
Transaction value based on SEC Form 4 reported price ($22.04); post-transaction value based on June 22 market close ($22.16).
Key questions
- What proportion of Bodenstedt's MoonLake Immunotherapeutics stake was involved in this transaction?
The sale represented 3.4% of direct holdings at the time, leaving a substantial direct ownership position of over 1.1 million shares after the transaction. - Did the transaction involve any indirect holdings or derivative instruments?
No; all shares sold were held directly, with no indirect entities, trusts, or option exercises involved, and Bodenstedt's indirect and derivative holdings remain at zero post-transaction.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close June 22) | $22.16 |
| Market capitalization | $1.5 billion |
| Net income (Loss) (TTM) | ($259.5 million) |
Company snapshot
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on novel immunotherapeutic solutions for inflammatory diseases. The company leverages its proprietary Nanobody platform to address significant unmet medical needs in immunology. Its strategy centers on advancing differentiated assets through clinical development to build a competitive edge in the inflammatory disease market.
- MoonLake Immunotherapeutics is advancing Sonelokimab, an investigational Nanobody-based therapy in Phase II trials targeting inflammatory diseases such as hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis.
- The company operates a clinical-stage biopharmaceutical model, generating value through drug development and potential future licensing or commercialization of its lead candidate.
- Primary customers are anticipated to be healthcare providers and specialists treating patients with chronic inflammatory conditions.
What this transaction means for investors
CFO Bodenstedt and CEO Jorge Santos da Silva both recently sold shares. However, the transactions, although from two significant executives, shouldn’t give investors cause for concern.
That’s because both were done via 10b5-1 trading plans. These plans are designed to avoid even the appearance of executives and members of the board of directors trading on material, non-public information. The plans set certain terms, like timing, ahead of time.
However, MoonLake Immunotherapeutics’ stock isn’t for the faint of heart. The shares crashed in late September, falling from over $60 to about $6. The stock big drop followed the release of a study’s results that investors found disappointing.
The stock price will remain sensitive to news about product development since the company doesn’t have any products approved by governments. Hence, it doesn’t generate any revenue.
Given that, most investors can’t predict the outcome and when, or even if, Moonlake Immunotherapeutics will produce revenue. And even if it did, there’s no telling when the company will operate profitably.
Should you buy stock in MoonLake Immunotherapeutics right now?
Before you buy stock in MoonLake Immunotherapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and MoonLake Immunotherapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $418,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,195,804!*
Now, it’s worth noting Stock Advisor’s total average return is 918% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of July 3, 2026.
Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
